Skip to content
Recall Observatory FDA recall evidence

Exact FDA event identifier

Event 93753

2 recalled-product records grouped only because every row carries this exact official event ID.

Open FDA event record

Event summary

Timeline bucket
January 05, 2024
Product types
Drug
Classifications
Class II
Statuses
Terminated
Recalling firm wording
Lupin Pharmaceuticals Inc.

Dossier provenance

Source snapshots represented here

  • openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Complete imported group

Every recalled product in this event

2 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 2

Rifampin Capsules USP 150mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured Lupin Limited, Aurangabad 431 210 INDIA, NDC 68180-658-06

D-0283-2024
Recall number
D-0283-2024
Initiated
January 05, 2024
Classification
Class II
Status
Terminated
Quantity
15,576 Bottles

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0
Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug and Failed Impurities/Degradation Specifications

Code information

A200816 exp 1/2024 A201248 exp 3/2024

Distribution pattern

Product was distributed to 32 Wholesale/distributor accounts who further distributed the product to 156 distribution sites.

drug · product 2 of 2

Rifampin Capsules USP 300mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured Lupin Limited, Aurangabad 431 210 INDIA, NDC 68180-659-06

D-0284-2024
Recall number
D-0284-2024
Initiated
January 05, 2024
Classification
Class II
Status
Terminated
Quantity
165,60 bottles

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0
Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug and Failed Impurities/Degradation Specifications

Code information

A200817 exp 1/2024

Distribution pattern

Product was distributed to 32 Wholesale/distributor accounts who further distributed the product to 156 distribution sites.